ADVERTISEMENT
Inside Interstitial Lung Disease: Overall Burden, Therapy Options, & Looking Ahead
A video interview series exploring interstitial lung disease burden, therapy, and future.
About the Speaker:
Ross Summer, MD, is a board certified pulmonary and critical care physician and an NIH-funded investigator. Dr Summer graduated medical school at Louisiana State University in New Orleans and completed his internship and medical residency training at Johns Hopkins Hospital in Baltimore, MD. After completing a 4-year Pulmonary and Critical Care Fellowship, Dr Summer spent 8 years on faculty at Boston University before moving to Thomas Jefferson University in Philadelphia in 2012. Dr Summer is currently a professor of medicine, the Section Chief of Pulmonary and Critical Care and Director of the Interstitial Lung Disease Program at Thomas Jefferson University Hospital. He also maintains an active laboratory and oversees clinical trials related to pulmonary fibrosis.
Navigating the Burden of Interstitial Lung Disease
For part 1 of this video series, Ross Summer, MD, professor of medicine, director of interstitial lung disease program, section chief of allergy, pulmonary and critical care medicine at Thomas Jefferson University, explains the incidence of interstitial lung disease and its burden on patients. Watch here.
Current Treatment, Management Landscape for ILD
Dr Ross Summer describes the current treatment landscape for interstitial lung disease, as well as shares some insight on landmark clinical trials in part 2 of a video series. Watch here.
Future of Care for Patients With Interstitial Lung Disease
In the third installment of this video series, Dr Ross Summer offers insight to payers on the care needed for interstitial lung disease and shares where he believes the future of care for this patient population is heading. Watch here.
Highlights From the Updated Clinical Practice Guideline for Progressive Pulmonary Fibrosis
Ross Summer, MD, professor of medicine, director of interstitial lung disease program, section chief of allergy, pulmonary and critical care medicine at Thomas Jefferson University, highlights the main takeaways from the 2022 updated guideline for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, including the conditional recommendation for nintedanib. Watch here.
